Clonal heterogeneity is defined as the presence of several subclones possessing different genomic alterations within a tumor.([@b1],[@b2]) Clonal heterogeneity has been associated with tumor development,([@b3]) invasion and metastasis,([@b4]) and poor clinical outcome.([@b5]) In regards to malignant lymphoma, there are some previous studies on clonal heterogeneity,([@b6],[@b7]) including our recent reports.([@b8]--[@b10]) We analyzed adult T-cell leukemia/lymphoma and found that clonal heterogeneity existed in approximately 70% of investigated cases.([@b11]) It was also found that cases of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) with clonal heterogeneity had a poorer prognosis compared with cases without heterogeneity.([@b9],[@b10])

Genomic alterations in cases with clonal heterogeneity are believed to contribute to clonal heterogeneity and several methods can be used to identify these alterations. Genomic alterations found in malignancies are somatic mutations, chromosomal translocations and copy number alterations (CNA). Tumors with many somatic mutations in general tend to lack CNA, while tumors with CNA have fewer somatic mutations.([@b12]) Therefore, it is important to choose an appropriate method to analyze genomic alterations for each tumor. Tumors with many somatic mutations require next-generation sequencing analysis, while tumors with CNA such as lymphoma are suitable for analysis by metaphase cytogenetics and/or array comparative genomic hybridization (CGH).([@b5])

Array CGH analysis is a powerful tool that can explore CNA in detail and evaluate tumor cell populations in biopsy samples, which comprise tumor cells with genomic alterations and normal cells without alterations. In this study, we developed a method of evaluating clonal heterogeneity by taking into account tumor cell populations, and extended our study to other types of lymphoma including Burkitt lymphoma, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) to investigate the relationship between clonal heterogeneity and clinicopathological features.

Materials and Methods
=====================

Patients for array comparative genomic hybridization analysis
-------------------------------------------------------------

We studied previously untreated 332 cases of lymphoma, comprising 29 cases of mantle cell lymphoma, 117 cases of DLBCL, 79 cases of Follicular lymphoma, 25 cases of Burkitt lymphoma, 31 cases of mucosa-associated lymphoid tissue (MALT) lymphoma and 51 peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). The patients were selected from those hospitalized between 1983 and 2004 at the Aichi Cancer Center hospital and hospitals related to Nagoya University Hospital. Lymphoma was diagnosed in accordance with World Health Organization classification criteria.([@b13]) The clinical features, hematologic characteristics, histology and immunophenotypes were reviewed by an expert hematopathologist (SN). Patients had received standard chemotherapy (mainly CHOP-like regimen). Clinical information is summarized in [Table S1](#SD11){ref-type="supplementary-material"}. This study was approved by the ethics committee of the Aichi Cancer Center Research Institute.

Analysis procedure of array comparative genomic hybridization data
------------------------------------------------------------------

### Array comparative genomic hybridization data

We analyzed data obtained from previous results of BAC array CGH for these 332 lymphoma samples.([@b14]--[@b18]) The array CGH glasses contained from 1778 to 2163 BAC clones (1.4--1.7 Mb resolutions). These clones were aligned with each of the chromosomes based on data from the National Center for Biotechnology Information (GRCh37) or from the University of California Santa Cruz (hg 19). Data can be accessed at <http://www.ncbi.nlm.nih.gov/gds>: Accession Number GSE54303.

### Background signal removal

In an effort to remove background signals from the array CGH data, the data obtained from 332 samples were treated individually. One objective sample was selected and Pearson\'s correlation coefficients between the objective sample and the other 331 samples were calculated, where the correlation was computed based on log~2~ ratios after manually removing obvious CNA. A subset of samples were then selected where the correlation coefficients to the object sample were \>0.5 (*P* = 4E-113). The median value of those selected samples for each probe was then taken as the background signal, and this value was subtracted from the log~2~ ratio of the objective sample. This procedure was repeated 332 times.

### Identification of copy number alterations and log~2~ ratio

We defined CNA on array CGH data by interactively updating and labeling a maximum likelihood segmentation model using SegAnnDB software.([@b19]) On each continuous CNA, an average of the log~2~ ratios was calculated.

### Calculation of tumor cell population from log~2~ ratio

The tumor cell population was calculated from the log~2~ ratio based on the functional relationship between the tumor cell population to the total cells in the sample (*X*) and the log~2~ ratio of CNA from array CGH data (*Y*):

for gain, while

where *n* is the gained or deleted chromosomal copy number on the CNA in tumor cells.

### Definition of clonal heterogeneity

We defined a case indicating the same log~2~ ratio for all CNA as a sample without clonal heterogeneity (Fig. [1](#fig01){ref-type="fig"}a) because the single tumor cell population was calculated from the log~2~ ratio(s) of all CNA in this sample. We defined a case having different log~2~ ratios in one sample as a sample with clonal heterogeneity (Fig. [1](#fig01){ref-type="fig"}a). Differences in log~2~ ratios were evaluated using Student\'s *t*-test (*P* \< 0.001) as previously described.([@b9]) In a few cases, the same tumor cell population was applied when the log~2~ ratios were proportional at variable copy numbers (one copy gain versus two copy gain) in the same sample. For example, a log~2~ ratio of 0.685 indicates a tumor cell population of 61% in a case of one copy gain and 0.39 is 63% in two copy gain ([Fig. S1](#SD1){ref-type="supplementary-material"}d). We defined such a case with different log~2~ ratios showing one tumor cell population as a sample without clonal heterogeneity.

![Results of array comparative genomic hybridization (CGH) analysis for cases with and without clonal heterogeneity. (a) A case without clonal heterogeneity showing a constant log~2~ ratio for all copy number alterations (CNA). (Top) The result of array CGH analysis with chromosomal regions on the *x*-axis and log~2~ ratios on the *y*-axis. There are four CNA (arrowheads) whose log~2~ ratios are −0.57. (Bottom) Log~2~ ratio and tumor cell population. The population of tumor cells with the CNA whose log~2~ ratio is −0.57 is calculated as 65% ([Fig. S1](#SD1){ref-type="supplementary-material"}a--c). This case is assessed as a sample without clonal heterogeneity since populations of tumor cells with each and every CNA in this sample are the same. (b) A case with clonal heterogeneity showing different log~2~ ratios. (Top) The result of array CGH analysis. There are two CNA (red up arrowheads) whose log~2~ ratio is 0.25, five CNA (red down arrowheads) whose log~2~ ratios are −0.30, and two CNA (black down arrowheads) whose log~2~ ratios are −0.62. (Bottom left) Log~2~ ratios and assessed tumor cell populations. This case is assessed as a sample with clonal heterogeneity because of the different tumor cell populations. (Bottom right) The simplest model of a tumor biopsy sample with different log~2~ ratios explained by clonal evolution. The solid box shows a tumor biopsy sample from a patient. It consists of 30% of normal cells (30%) and 70% of tumor cells (70%, dotted box). The tumor cells consist of a subclone (32%, left) and the other subclone (38%, right), which can have evolved from the subclone in the left.](cas0105-0897-f1){#fig01}

### Statistics

Statistical analysis included Student\'s *t*-test, Fisher\'s exact test, the Cox proportional hazard model and Kaplan--Meier analysis, which were performed using the free software R (<http://www.r-project.org/>).

### Analysis of published data

We also studied the existence of clonal heterogeneity in MALT lymphoma samples using independently published data.([@b20]) Data was obtained from <http://www.ncbi.nlm.nih.gov/gds>; Accession Number GSE35278.

Results
=======

Assessment of clonal heterogeneity using array comparative genomic hybridization data
-------------------------------------------------------------------------------------

### Identification of copy number alterations

We identified CNA for 332 malignant lymphoma cases using array CGH data. Of these, 51 cases showed no CNA and were removed from further analysis. The removed cases were 13 of the 79 cases of follicular lymphoma, five of the 25 cases of Burkitt lymphoma, 21 of the 31 cases of MALT lymphoma, and 12 of the 51 cases of PTCL-NOS. In the remaining 281 samples, one to 38 (8.5 ± 6.5, mean ± SD) CNA per sample were identified. When the log~2~ ratio of each CNA was examined, some cases showed different log~2~ ratios in a sample (Fig. [1](#fig01){ref-type="fig"}a). Detailed analysis suggested that several subclones with different CNA existed in such cases.

### Assessment of clonal heterogeneity

The average log~2~ ratios of identified CNA were used to calculate tumor cell populations for the examination of clonal heterogeneity. When a sample does not contain any normal tissue components (e.g. cell lines), the log~2~ ratio is calculated as shown in [Figure S1](#SD1){ref-type="supplementary-material"}(a). However, a tumor biopsy sample consists of tumor cells with CNA and normal cells without any CNA ([Fig. S1](#SD1){ref-type="supplementary-material"}b). We can evaluate an average chromosomal copy number for a sample containing a mixture of tumor cells and a normal tissue component using the formula shown in [Figure S1](#SD1){ref-type="supplementary-material"}(c). Therefore, the percentage of tumor cells can be assessed by the log~2~ ratio of such CNA. When all CNA in a sample show the same log~2~ ratio, the case is assessed as a sample without clonal heterogeneity because the population of tumor cells with each CNA is the same in that case (Fig. [1](#fig01){ref-type="fig"}a). A case with different log~2~ ratios is assessed as a sample with clonal heterogeneity because there were different populations of tumor cells with different CNA in most cases. Clonal evolution is suggested to have taken place in such cases (Fig. [1](#fig01){ref-type="fig"}a).

### Assessment by G-banding of method for the examination of clonal heterogeneity

Assessment of the method employed for the examination of clonal heterogeneity based on array CGH analysis was performed using G-banding analysis. Sometimes the same tumor cell population was determined from different log~2~ ratios of array CGH analysis in a sample, indicating that there are CNA with different chromosomal copy numbers in a tumor clone. G-banding revealed that CNA were present with different copy numbers in such cases ([Fig. S1](#SD1){ref-type="supplementary-material"}d), indicating that the method employed for the examination of clonal heterogeneity accurately reflected the karyotype.

Incidence of clonal heterogeneity
---------------------------------

The 281 cases of six types of lymphoma were assessed for clonal heterogeneity based on the method described above. Incidence of clonal heterogeneity varied significantly among lymphoma types, from 25% (Burkitt lymphoma) to 69% (mantle cell lymphoma; Table [1](#tbl1){ref-type="table"}, *P* = 0.003 by Fisher\'s exact test). Incidence of clonal heterogeneity also varied among lymphoma subtypes. It differed between GCB-DLBCL and ABC-DLBCL ([Table S2](#SD12){ref-type="supplementary-material"}, 28% and 64%, *P* = 0.007). It was correlated with stages in follicular lymphoma ([Table S3](#SD13){ref-type="supplementary-material"}, 17%, 29%, 33% and 44% in stage I, II, IIIa and IIIb, respectively). In cases of MALT lymphoma, any CNA did not exist in cases with t(11:18) and clonal heterogeneity was only found in cases without t(11:18). This result was confirmed using independent published data ([Table S4](#SD14){ref-type="supplementary-material"}).([@b20])

###### 

Sample number for array CGH analysis and incidence of clonal heterogeneity for each types of lymphoma

  Type of lymphoma   Total sample number   Number of samples without CNA   Samples with CNA   
  ------------------ --------------------- ------------------------------- ------------------ -----
  MCL                29                    0                               29 (20)            69%
  DLBCL              117                   0                               117 (55)           47%
  FL                 79                    13                              66 (19)            29%
  BL                 25                    5                               20 (5)             25%
  MALT               31                    21                              10 (3)             30%
  PTCL-NOS           51                    12                              39 (16)            41%
  Total              332                   51                              281 (118)          42%

CGH, comparative genomic hybridization; CNA, copy number alterations; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.

Numbers of copy number alterations for samples with and without clonal heterogeneity
------------------------------------------------------------------------------------

Numbers of CNA were compared between cases with and without clonal heterogeneity (Table [2](#tbl2){ref-type="table"}). The average numbers of CNA were significantly higher for the cases with clonal heterogeneity than those without clonal heterogeneity for any types of lymphoma (Table [2](#tbl2){ref-type="table"}). The averages varied significantly among each type of lymphoma, from 2.4 (MALT) to 7.8 (DLBCL) in cases without clonal heterogeneity and from 5.3 (MALT) to 16.9 (PTCL-NOS) in cases with clonal heterogeneity.

###### 

Number of CNA regions for each type of lymphoma

  --
  --

Differences of chromosomal regions and frequencies of copy number alterations between cases with and without clonal heterogeneity
---------------------------------------------------------------------------------------------------------------------------------

Chromosomal regions and frequencies of CNA were compared between cases with and without clonal heterogeneity (Fig. [2](#fig02){ref-type="fig"}, [Fig. S2](#SD2){ref-type="supplementary-material"}--7; Table [3](#tbl3){ref-type="table"}). Recurrent CNA among various types of lymphoma with clonal heterogeneity were found to be 8q24.1 (minimal overlapping lesion: *MYC*) gain, 9p21.3 (*CDKN2A/2B*) loss and 17p13 (*TP53*, *ATP1B2*, *SAT2*, *SHBG*) loss. The 8p24.1 (*MYC*) gain was found in significantly more cases with clonal heterogeneity than in those without clonal heterogeneity in follicular lymphoma and PTCL-NOS. The 9p21.3 loss was found in mantle cell lymphoma, DLBCL and PTCL-NOS. The 17p13 loss was found in mantle cell lymphoma, DLBCL, Burkitt lymphoma and PTCL-NOS (Fig. [3](#fig03){ref-type="fig"}).

###### 

Differences in CNA between samples with and without clonal heterogeneity (more than 25% differences)

  Types of lymphoma   Clonal heterogeneity (−)                                                  Clonal heterogeneity (+)   Detailed in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------- ------------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  MCL                 ---                                                                       ---                        6q21, **[8q13.3--q24.23]{.ul}**[†](#tf3-1){ref-type="table-fn"}                                                                                                                                                      1p22.1--q12, 5q23.1,[§](#tf3-3){ref-type="table-fn"} 7q36.3, 8p23.3--11.21, **[9p24.3--q31.1,]{.ul}**[¶](#tf3-4){ref-type="table-fn"} **[17p13.3--11.2]{.ul}**[††](#tf3-5){ref-type="table-fn"}                                                                                                           [Figure S2](#SD2){ref-type="supplementary-material"}
  DLBCL               ---                                                                       ---                        19q13.12--.43                                                                                                                                                                                                        **[9p21.3]{.ul},**[¶](#tf3-4){ref-type="table-fn"} **[17p13. 2--11. 2]{.ul}**[††](#tf3-5){ref-type="table-fn"}                                                                                                                                                                                            Figure[2](#fig02){ref-type="fig"}
  FL                  ---                                                                       ---                        2p16.1--14, 7p11.1, 7q31.1--.2, [‡](#tf3-2){ref-type="table-fn"} **[8q22.1--24.23]{.ul}**,[†](#tf3-1){ref-type="table-fn"} 9q12--34.3,[‡](#tf3-2){ref-type="table-fn"} 10p15.3--13, 12p13.33--q21.1, 18p11.21--q23   ---                                                                                                                                                                                                                                                                                                       [Figure S3](#SD3){ref-type="supplementary-material"}
  BL                  1q44, 12p13.33--q24.33, 15q22.32--15q25.1                                 ---                        1q25.2, 3q26.33--29, 13q31.3--32.3, 17q23.1--24.1                                                                                                                                                                    6p25.3--22.3, q13--21, 10q23.33--24.1, 11q23.3--25, 14q11.1--32.33,[‡‡](#tf3-6){ref-type="table-fn"} 16q24.3, **[17p13.3--q12]{.ul}**[††](#tf3-5){ref-type="table-fn"}                                                                                                                                    [Figure S4](#SD4){ref-type="supplementary-material"}
  MALT                1p36.33--.32, 2q14.3, 3p26.3--q29^,^ 5q31.1, 10p12.31--.1, 18q11.2 -q23   ---                        13q34, 20p11.22--q12, 22q11.21                                                                                                                                                                                       7q31.31--q34, 20p12.1                                                                                                                                                                                                                                                                                     [Figure S5](#SD5){ref-type="supplementary-material"}
  PTCL-NOS            5p15.1                                                                    ---                        7q21.11--q35,[‡](#tf3-2){ref-type="table-fn"} **[8q24.13--.21]{.ul}**,[†](#tf3-1){ref-type="table-fn"} 9q33.3--34,[‡](#tf3-2){ref-type="table-fn"} 16p13.3--11.1, 17q21.2--25.3                                      2p23.3, q21.3--37.3, 4p16.1--15.2, 5q14.3--34,[§](#tf3-3){ref-type="table-fn"} **[9p21.3--q31.1,]{.ul}**[¶](#tf3-4){ref-type="table-fn"} 10q11.1--q23.31, 12p13.1--.13, 13q21.31--34, 14q13.1--32.12,[‡‡](#tf3-6){ref-type="table-fn"} 15q23, **[17p13.3--11.2]{.ul}**[††](#tf3-5){ref-type="table-fn"}   [Figure S6](#SD6){ref-type="supplementary-material"}
  All lymphomas       ---                                                                       ---                        ---                                                                                                                                                                                                                  **[9p21.3,]{.ul}**[¶](#tf3-4){ref-type="table-fn"} **[17p13.3--11.2]{.ul}**[††](#tf3-5){ref-type="table-fn"}                                                                                                                                                                                              [Figure S7](#SD7){ref-type="supplementary-material"}

Common aberrations more than two lymphomas are indicated in bold with underline.

Aberration is found in MCL, FL and PTCL-NOS;

aberration found in FL and PTCL-NOS;

aberration found in MCL and PTCL-NOS;

aberration found in MCL, DLBCL and PTCL-NOS;

aberration found in MCL, DLBCL, BL and PTCL-NOS;

aberration found in BL and PTCL-NOS. ---, no region is identified; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.

![Chromosomal regions and frequencies of copy number alterations (CNA) for DLBCL with and without clonal heterogeneity. (a) CNA for 55 diffuse large B-cell lymphoma (DLBCL) cases with clonal heterogeneity. The *x*-axis represents chromosomal regions and the *y*-axis represents frequencies of gain (above 0) or loss (below 0). (b) CNA for 62 DLBCL cases without clonal heterogeneity. The profile of cases without clonal heterogeneity resembles those of cases with clonal heterogeneity (a) while loss of 9p and 17p are less common in cases without heterogeneity than in those with (arrowheads). (c) Differences in CNA between DLBCL with and without clonal heterogeneity. (Top) Subtraction of frequencies of gain in cases without clonal heterogeneity (b, red area) from those with (a, red area). The *y*-axis represents differences in frequency (\>0: higher frequencies in cases with clonal heterogeneity; \<0: higher frequencies in those without clonal heterogeneity). The characteristic gain in DLBCL cases with clonal heterogeneity is 19p (arrowhead) with more than 25% differences between cases with and without clonal heterogeneity. (Bottom) Subtraction of frequencies of loss in cases without clonal heterogeneity (b, blue area) from those with clonal heterogeneity (a, blue area). The *y*-axis represents differences (\>0: higher frequencies in cases with clonal heterogeneity; \<0: higher frequencies in those without clonal heterogeneity). The characteristic loss in DLBCL cases with clonal heterogeneity are 9p and 17p (arrow heads). All gain and loss with differences \>25% are summarized in Table [3](#tbl3){ref-type="table"}.](cas0105-0897-f2){#fig02}

![Various types of lymphoma cases with or without 8q24.1 gain, 9p21.3 loss and 17p13.1 loss. Cases without clonal heterogeneity (left) are compared with those with clonal heterogeneity (right). Lymphoma types are shown over each box. Red, black and white boxes indicate cases with gain, with loss, and without loss and gain, respectively; the upper, middle and lower lanes of the boxes represent 8p24.1 (MYC locus), 9p21.3 (CDKN2A) and 17p13.1 (TP53), respectively. \**P* \< 0.05 and \*\**P* \< 0.01 by Fisher\'s exact test.](cas0105-0897-f3){#fig03}

Relationship between clonal heterogeneity and clinical outcomes
---------------------------------------------------------------

Survival analysis revealed that clonal heterogeneity was correlated with poor prognosis in several types of lymphoma. Significantly poor prognosis was found in mantle cell lymphoma (*P* = 0.005) and DLBCL (*P* = 6e-5; Fig. [4](#fig04){ref-type="fig"}). Burkitt lymphoma and PTCL-NOS also showed a poorer prognosis in cases with clonal heterogeneity than those without clonal heterogeneity, although the differences were not statistically significant (*P* = 0.17 and *P* = 0.15, [Fig. S10](#SD10){ref-type="supplementary-material"}b,c). There was no difference between cases with clonal heterogeneity and those without for cases involving follicular lymphoma (*P* = 0.7, [Fig. S10](#SD10){ref-type="supplementary-material"}a). Because all patients with MALT lymphoma were alive, statistical analysis was not performed.

![Clonal heterogeneity correlated with poor prognosis. (a) Kaplan--Meier analysis to compare survival in mantle cell lymphoma patients with and without clonal heterogeneity. Patients with clonal heterogeneity demonstrated a poorer prognosis than those without. (b) Kaplan-Meier analysis in diffuse large B-cell lymphoma (DLBCL) patients. Patients with clonal heterogeneity demonstrated poorer prognosis than those without clonal heterogeneity.](cas0105-0897-f4){#fig04}

Monovariate analysis was conducted on the factors affecting prognosis in mantle cell lymphoma and DLBCL. The results revealed that IPI (international prognostic Index; *P* = 0.03 for mantle cell lymphoma, *P* = 0.002 for DLBCL) and clonal heterogeneity (*P* = 0.02 and *P* = 0.00005, respectively) were correlated with prognosis in both of mantle cell lymphoma and DLBCL (Table [4](#tbl4){ref-type="table"}). 9p21.3 (*CDKN2A*) loss was correlated with poor prognosis in DLBCL (*P* = 0.001) and 17p13.1 (*TP53*) loss was correlated in mantle cell lymphoma (*P* = 0.02). Multivariate analysis compared IPI, number of CNA, clonal heterogeneity, 8q24.1 (*MYC*) gain, 9p21.3 loss and 17p13.1 loss. It demonstrated that IPI (*P* = 0.0009), clonal heterogeneity (*P* = 0.006) and 8q24.1 gain (*P* = 0.005) were associated with a poor prognosis for mantle cell lymphoma while clonal heterogeneity (*P* = 0.0003) and 9p21.3 loss (*P* = 0.003) were associated with a poor prognosis for DLBCL (Table [4](#tbl4){ref-type="table"}). Clonal heterogeneity was confirmed by multivariate analysis as an independent predictor of poor prognosis for both types of lymphoma.

###### 

Monovariate and multivariate analysis of prognostic factors affecting overall survival

                                                                         Mantle cell lymphoma (*n* = 26)   DLBCL (*n* = 84)                        
  ------------------------- ------------------- ------------------------ --------------------------------- ------------------- ------------------- -------
  Monovariate analysis      IPI                 High intermediate/High   2.67 (1.12--6.37)                 0.03                2.66 (1.45--4.88)   0.002
  Number of CNA(s)          More than 7         4.25 (1.56--11.55)       0.005                             1.89 (0.97--3.68)   0.06                
  Clonal heterogeneity      Heterogeneity (+)   3.81 (1.25--11.63)       0.02                              3.70 (1.97--6.96)   0.00005             
  8q24.2 (*MYC* locus)      Gain                2.16 (0.9--5.22)         0.09                              1.06 (0.55--2.02)   0.9                 
  9p21.3 (*CDKN2A* locus)   Loss                2.32 (0.94--5.76)        0.07                              2.78 (1.51--5.13)   0.001               
  17p13.1 (*TP53* locus)    Loss                3.14 (1.18--8.38)        0.02                              1.26 (0.69--2.29)   0.4                 
  Multivariate analysis     IPI                 High intermediate/High   7.15 (2.25--22.77)                0.0009              1.66 (0.87--3.18)   0.1
  Number of CNA(s)          More than 7         3.59 (0.96--13.36)       0.06                              1.72 (0.8--3.72)    0.2                 
  Clonal heterogeneity      Heterogeneity (+)   8.06 (1.8--36.15)        0.006                             4.16 (1.93--8.98)   0.0003              
  8q24.2 (*MYC* locus)      Gain                8.11 (1.86--35.42)       0.005                             1.4 (0.67--2.92)    0.4                 
  9p21.3 (*CDKN2A* locus)   Loss                4.94 (1.02--24.03)       0.05                              2.69 (1.4--5.14)    0.003               
  17p13.1 (*TP53* locus)    Loss                1.54 (0.3--7.75)         0.6                               2.03 (0.9--4.61)    0.09                

CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index.

Discussion
==========

We have developed a method for the assessment of clonal heterogeneity by taking into account the normal tissue components in a tumor sample. Based on such an analysis, we investigated the presence of clonal heterogeneity in 332 cases comprising six types of lymphoma, and found relationships between clonal heterogeneity and poor prognosis and recurrent CNA.

Clonal heterogeneity was associated with poor prognosis in several types of lymphoma. Cases with clonal heterogeneity showed significantly poorer prognosis in mantle cell lymphoma and DLBCL (Fig. [4](#fig04){ref-type="fig"}). Cases with clonal heterogeneity also showed poorer prognosis, although not significantly, in Burkitt lymphoma and PTCL-NOS ([Fig. S10](#SD10){ref-type="supplementary-material"}b,c), and showed no difference in prognosis in follicular lymphoma ([Fig. S10](#SD10){ref-type="supplementary-material"}a). One reason for the poor prognosis may relate to clonal evolution of the tumor cells, which could have taken place in cases with clonal heterogeneity (Fig. [1](#fig01){ref-type="fig"}b). Recently, prognostic biomarkers in several types of lymphoma have been identified by analysis based on next-generation sequencing or SNP array,([@b21]--[@b27]) such as somatic mutations of *notch 1* and *2*([@b26],[@b28]) and *TP53*.([@b29]) In addition to somatic mutations, CNA,([@b30],[@b31]) aberrant mRNA expression,([@b32]--[@b34]) and cell surface markers([@b35]) have also been identified as prognostic biomarkers. Our current analysis examined the presence of clonal heterogeneity in lymphoma cases and found a correlation between clonal heterogeneity and poor clinical outcome. Therefore, the evaluation of clonal heterogeneity could potentially be adopted as a new biological marker and the combination of this marker and previously established prognostic biomarkers could contribute toward the more accurate prediction of clinical outcome for B and T-cell lymphoma.

Cases with clonal heterogeneity irrespective of lymphoma type indicated recurrent CNA: gain of *MYC*, loss of *CDKN2A/2B* and loss of *TP53* (Table [3](#tbl3){ref-type="table"}; Fig. [3](#fig03){ref-type="fig"}). Messenger RNA expression of TP53 was lower in DLBCL cases (*P* = 0.04, data not shown). Aberrations of these oncogene and tumor suppressor genes could contribute toward clonal heterogeneity by promoting and/or progressing lymphoma in various ways. For example, overexpression of *MYC* stimulates tumor cell proliferation, *TP53* loss inhibits apoptosis, including apoptosis induced by overexpression of *MYC*, and *CDKN2A/2B* loss damages cell cycle checkpoint responses. Although it is not known whether these CNA were generated during clonal evolution or as an early event during lymphoma development, it is important to note that these oncogene and tumor suppressor genes reported in a variety of tumors([@b36]--[@b38]) were also involved in cases with clonal heterogeneity.

Although the relationships between clonal heterogeneity and recurrent CNA and poor prognosis irrespective of lymphoma type were shown, distinctive features of each lymphoma types were also shown in our analysis. The incidence of clonal heterogeneity varied among lymphoma types (Table [1](#tbl1){ref-type="table"}) and subtypes ([Table S2](#SD12){ref-type="supplementary-material"}--[4](#SD14){ref-type="supplementary-material"}). In addition to the incidence of clonal heterogeneity, the numbers of CNA also varied among lymphoma types (Table [2](#tbl2){ref-type="table"}). Moreover, examination of chromosomal regions and frequency of CNA indicated distinct differences among lymphoma types (Fig. [2](#fig02){ref-type="fig"}; [Fig. S2](#SD2){ref-type="supplementary-material"}--[S7](#SD7){ref-type="supplementary-material"}) and subtypes ([Fig. S8](#SD8){ref-type="supplementary-material"}--9). These distinctive differences might reflect physiological and pathological differences among lymphoma types. Beyond these differences, clonal heterogeneity was present in all types of lymphoma.

In summary, we have developed a method of evaluating clonal heterogeneity based on array CGH analysis by taking into account tumor cell populations and found in the present study that clonal heterogeneity was present in every type of lymphoma. The relationships between clonal heterogeneity and poor prognosis and recurrent CNA were identified. These findings suggest that the evaluation of clonal heterogeneity could potentially be adopted as a new biological marker, and that the combination of this marker and previously established prognostic biomarkers could contribute toward the more accurate prediction of clinical outcome for B and T-cell lymphoma.
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**Fig. S1.** Method for calculating a tumor cell population using the result of array comparative genomic hybridization (CGH) analysis.

###### 

**Fig. S2.** Chromosomal regions and frequencies of copy number alterations (CNA) for mantle cell lymphoma with or without clonal heterogeneity.

###### 

**Fig. S3.** Chromosomal regions and frequencies of copy number alterations (CNA) for follicular lymphoma with and without clonal heterogeneity.

###### 

**Fig. S4.** Chromosomal regions and frequencies of copy number alterations (CNA) for Burkitt lymphoma with or without clonal heterogeneity.

###### 

**Fig. S5.** Chromosomal regions and frequencies of copy number alterations (CNA) for mucosa-associated lymphoid tissue (MALT) lymphoma with and without clonal heterogeneity.

###### 

**Fig. S6.** Chromosomal regions and frequencies of copy number alterations (CNA) for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) with and without clonal heterogeneity.

###### 

**Fig. S7.** Chromosomal regions and frequencies of copy number alterations (CNA) for all lymphoma with and without clonal heterogeneity.

###### 

**Fig. S8.** Chromosomal regions and frequencies of copy number alterations (CNA) for ABC-diffuse large B-cell lymphoma (DLBCL) with and without clonal heterogeneity.
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**Fig. S9.** Chromosomal regions and frequencies of copy number alterations (CNA) for GCB-diffuse large B-cell lymphoma (DLBCL) with and without clonal heterogeneity.
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**Fig. S10.** Survival differences between cases with and without clonal heterogeneity in each type of lymphoma.
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**Table S1.** Clinical information and summary of analysis for 332 malignant lymphoma cases.
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**Table S2.** Incidence of clonal heterogeneity for diffuse large B-cell lymphoma (DLBCL) subgroups.
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**Table S3.** Incidence of clonal heterogeneity for follicular lymphoma.
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**Table S4.** Incidence of clonal heterogeneity of mucosa-associated lymphoid tissue (MALT) lymphoma with or without MALT1 translocation.
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